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Abstract
Purpose To assess the impact of hepatic or renal impairment
on the pharmacokinetics (PK) of edivoxetine.
Methods Two separate multi-center, open-label studies with
males and females were conducted. Subjects were categorized
according to their hepatic function, determined by the Child–
Pugh classification, or renal function, determined by creatinine
clearance using the Cockcroft–Gault equation. Subjects re-
ceived a single dose of 18 mg in the hepatic impairment study
or 6 mg in the renal impairment study. Noncompartmental PK
parameters were computed from the edivoxetine plasma
concentration–time data.
Results In the hepatic study, the geometric least squares mean
(GLSM) and 90 % confidence interval (CI) of the ratio [im-
paired : normal] of area under the concentration versus time
curve from time zero to infinity (AUC0-∞; h×ng/mL) was
1.24 (0.93, 1.64) in the mild, 1.60 (1.21, 2.12) in the moderate,
and 1.70 (1.28, 2.24) in the severe group. In the renal impair-
ment study, the GLSM (90 % CI) of the ratio [impaired :
normal] of AUC0-∞ was 1.13 (0.73, 1.73) in mild, 1.90
(1.28, 2.82) in moderate, 1.55 (0.94, 2.55) in severe, and
1.03 (0.66, 1.59) in ESRD groups. Overall, the GLSM of the
ratio [impaired : normal] of Cmax was slightly less than or
approximately 1 across the hepatic and renal impairment
groups. Across both studies, there were no clinically signifi-
cant changes in vital signs and laboratory values, the adverse
events were mild in severity and mostly related to nervous
system and gastrointestinal disorder-related events.
Conclusions PK changes in subjects with hepatic or renal
impairment were of small magnitude and did not appear to
impact overall subject tolerability. Daily dosing of edivoxetine
in a larger population of impaired subjects, including those
with dual impairment, would aid in establishing edivoxetine
tolerability and PK in a clinical practice scenario.
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Introduction
Edivoxetine (LY2216684 HCl; 2-Morpholinemethanol,
α-[(5-fluoro-2-methoxyphenyl) methyl]-α-[tetrahydro-2H-
pyran-4-yl]-, hydrochloride, [αR, 2S]) is a potent and highly
selective norepinephrine reuptake inhibitor being evaluated as
adjunctive treatment for adult patients with major depressive
disorder (MDD) who are taking a selective serotonin reuptake
inhibitor. Edivoxetine was studied in two double-blind
investigations in adult patients with MDD [1, 2] and an
open-label study in pediatric patients with attention deficient
hyperactivity disorder [3, 4].
The patient population for edivoxetine potentially includes
those with hepatic or renal impairment, which might affect the
pharmacokinetics (PK) of edivoxetine and may lead to
changes in the safety, tolerability, and/or efficacy of the drug.
Two distinct studies were conducted to assess the impact of
hepatic impairment and renal impairment on the PK of
edivoxetine. In the hepatic impairment study, the primary
objective was to evaluate the PK of edivoxetine in subjects
The clinical trial registry number for the study conducted in subjects with
compromised hepatic function is NCT01241435. Note that the Phase I
trial conducted in subjects with compromised renal function is not
included in a public registry.
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with mild, moderate, or severe hepatic impairment compared
to subjects with normal hepatic function after a single oral
dose of 18 mg edivoxetine. In the renal impairment study, the
primary objective was to evaluate the PK of edivoxetine in
subjects with mild, moderate, and severe renal impairment or
end-stage renal disease (ESRD) compared to subjects with
normal renal function after a single oral dose of 6 mg
edivoxetine. A secondary objective of the renal impairment
study was to assess the impact of dialysis on the PK of
edivoxetine in subjects with ESRD. Both of these studies
assessed the safety and tolerability of edivoxetine. The results




This study was an open-label, single-dose, parallel-design,
multi-center study involving subjects who were categorized
into four groups by their hepatic function, as defined by the
Child–Pugh criteria [5, 6]: normal hepatic function, hepatic
impairment due to liver cirrhosis classified as mild (Child-
Pugh A), hepatic impairment due to liver cirrhosis classified
as moderate (Child-Pugh B), and hepatic impairment due to
liver cirrhosis classified as severe (Child-Pugh C). At the time
of screening, subjects were between 40 and 64 years old with a
body mass index (BMI) of 17.4 to 35 kg/m2. Subjects with
normal hepatic function were required to be healthy as deter-
mined by medical history and a physical examination and to
have clinical laboratory test results within normal reference
ranges or with acceptable deviations deemed to be without
clinical significance. Efforts were made to match subjects
across groups in terms of age (±10 years), weight (±10 kg),
and sex. Each subject was screened up to 30 days prior to
enrollment. Subjects were admitted to the Clinical Research
Unit (CRU) on the day prior to dosing of edivoxetine and
resided at the CRU for at least 72 h after edivoxetine was
administered, except for severe hepatic impairment subjects
who remained at the CRU for at least 120 h after edivoxetine
was administered. Administration of the doses was preceded
by a light breakfast given within 1 h of dosing. A total dose of
18 mg of edivoxetine was given as three 6-mg tablets. Ap-
proximately 7 days following discharge from the study each
subject returned for a follow-up visit.
Renal impairment
This study was a multi-center, open-label, 1-period study
involving subjects who were categorized by their renal
function as normal, and mild, moderate, or severe renal im-
pairment, or as ESRD undergoing hemodialysis, based on
estimated creatinine clearance (CLCR) by the Cockcroft–Gault
(CG) equation as described in the 2010 FDA guidance [7].
Normal, mild, moderate, and severe renal function was de-
fined by an estimated CLCR of ≥90mL/min, 60 to 89 mL/min,
30 to 59 mL/min, and 15 to 29 mL/min, respectively. Subjects
were 37 to 78 years of age with a BMI of 20.2 to 38.7 kg/m2 at
the time of screening. Subjects with normal renal function
were required to be healthy as determined by medical history
and a physical examination, with clinical laboratory test re-
sults within normal reference ranges or with acceptable devi-
ations deemed to be without clinical significance. Efforts were
made to match subjects across groups in terms of age
(±10 years), weight (±10 kg), sex, and race. Each subject
was screened up to 21 days prior to enrollment. Renal impair-
ment was assessed using the serum creatinine level when the
subjects were admitted to the CRU. The ESRD subjects on
hemodialysis were required to have been receiving hemodial-
ysis for at least 3 months prior to enrollment.
Subjects were admitted to the CRU the night before they
were scheduled to receive edivoxetine. After an 8-hour fast
from food and a 1-hour water restriction, subjects not on
hemodialysis were given a single 6-mg tablet of edivoxetine
followed by a 4-hour fast. Water was restricted for 2 h
postdose as well. Those subjects on hemodialysis received
6 mg edivoxetine followed by a 4-hour fast on two separate
occasions to allow for a comparison of the effect of hemodi-
alysis on edivoxetine PK. Subjects completed a dialysis
session, and then waited at least 18 h before taking the first
6-mg dose of edivoxetine. Approximately 48 h following
edivoxetine administration subjects resumed their dialysis
cycle. After at least 1 week from edivoxetine administration,
the second 6-mg dose of edivoxetine was administered ap-
proximately 2 h prior to the start of a dialysis session. To
eliminate potential variation arising from different types of
hemodialysis membranes, only high-flux polysulfone mem-
branes were used for hemodialysis. All subjects were
discharged from the CRU after 24-hour postdose procedures
at the discretion of the investigator. A follow-up visit occurred
approximately 7 days following discharge for all subjects.
Pharmacokinetics
Blood sampling
In the hepatic study, blood samples were collected for the
measurement of plasma concentrations of edivoxetine up to
72 h postdose for all subjects, except those with severe hepatic
impairment whose samples were collected up to 120 h
postdose. In the renal study, blood samples were collected for
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the measurement of the plasma concentration of edivoxetine up
to 72 h postdose for all subjects.
Bioanalysis
Plasma samples were analyzed for edivoxetine concentra-
tions using a validated liquid chromatography assay with
tandem mass spectrometry detection. Plasma samples
were analyzed at Covance Laboratories Inc. located in
Madison, Wisconsin, USA. The lower limit of quantifica-
tion was 0.20 ng/mL, and the upper limit of quantification
was 100.00 ng/mL. The interassay accuracy during vali-
dation ranged from −3.5 % to 2.7 %. The interassay
precision described as percent relative standard deviation
during validation ranged from 1.4 % to 4.5 %. Edivoxetine
was stable in plasma for up to 364 days when stored at
approximately −20 °C and −70 °C.
Pharmacokinetic and statistical analysis
Pharmacokinetic parameters were computed by standard
noncompartmental methods of analysis usingWinNonlin Pro-
fessional Version 5.2. The PK parameters computed included
area under the concentration versus time curve from time zero
to infinity (AUC0-∞; unit: h×ng/mL), half-life associated
with the terminal rate constant (t1/2; unit: h), apparent total
body clearance (CL/F; unit: L/h), and apparent volume of
distribution during the elimination phase (VZ/F; unit: L). The
maximum observed drug concentration (Cmax; unit: ng/mL) and
the time of Cmax (tmax; unit: h) was determined from the PK
profile.
Statistical analysis was conducted on log transformed
AUC0-∞ and Cmax using an analysis of variance model with
group as a fixed factor. The primary outcome of the analysis
was the ratio of geometric least squares means (GLSM) and
their corresponding 90 % confidence intervals (CI) of
AUC0-∞ and Cmax between the renal impairment or hepatic
impairment groups versus the respective normal function
group.
A continuous analysis using linear regression was
performed to evaluate the relationship between estimated
CLCR and edivoxetine CL/F from the renal study. Similarly,
Child–Pugh score and edivoxetine CL/F from the hepatic
study was evaluated.
Safety and tolerability
For both studies, safety and tolerability were assessed by
means of vital signs measurement, physical examinations,




The demographic data for subjects participating in the
hepatic impairment study (N =36) and renal impairment study
(N =42) is shown in Table 1.
Pharmacokinetics
Hepatic impairment
The PK profiles resulting from a single oral dose of 18 mg of
edivoxetine administered to subjects with normal hepatic
function and varying degrees of hepatic impairment are illus-
trated in Fig. 1. An increase in AUC0-∞ and t1/2, a decrease in
CL/F and Cmax, and minimal to no change in tmax and Vz/F
was observed in subjects with hepatic impairment (Table 2).
The GLSM (90 % CI) of the ratio [impaired : normal] of
AUC0-∞ was 1.24 (0.93, 1.64) in the mild, 1.60 (1.21, 2.12)
in the moderate, and 1.70 (1.28, 2.24) in the severe group. The
GLSM (90 % CI) of the ratio [impaired : normal] of Cmax was
0.85 (0.69, 1.03) in the mild, 0.89 (0.73, 1.09) in the moderate,
and 0.74 (0.61, 0.91) in the severe group.
The relationship between Child–Pugh score and
edivoxetine CL/F is illustrated in Fig. 2. The estimate of the
slope of the linear regression was −1.80 with a p-value of
0.0781 and a correlation coefficient of 0.3665. These results
indicate the slope of the linear regression was not statistically
significant, and there was a lack of an apparent correlation
between Child–Pugh score and CL/F.
Renal impairment
The PK profiles resulting from a single oral dose of 6 mg of
edivoxetine administered to subjects with normal renal func-
tion and varying degrees of renal impairment are illustrated in
Fig. 3. In general, an increase in AUC0-∞ and t1/2, a decrease
in CL/F, and minimal to no change in tmax, Cmax and V/F was
observed in subjects with renal impairment (Table 2). The
GLSM (90 % CI) of the ratio [impaired : normal] of
AUC0-∞ was 1.13 (0.73, 1.73) in mild, 1.90 (1.28, 2.82) in
moderate, 1.55 (0.94, 2.55) in severe, and 1.03 (0.66, 1.59) in
ESRD groups. The AUC0-∞ 90 % CIs of all the renal impair-
ment groups included unity except for the moderate group.
The GLSM (90 % CI) of the ratio [impaired : normal] of Cmax
was 0.79 (0.54, 1.16) in mild, 1.06 (0.75, 1.51) in moderate,
1.10 (0.70, 1.72) in severe, and 0.84 (0.56, 1.24) in ESRD.
Hemodialysis did not appear to have any meaningful impact
on the PK of edivoxetine in ESRD subjects (Table 2). For the
two subjects with ESRD not receiving hemodialysis (see
Table 1), the AUC0-∞ was 133 h×ng/mL and 409 h×ng/mL,
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and the Cmax was 18.4 ng/mL and 18.6 ng/mL. These two
subjects were not included in the summary of PK parameters
(Table 2) or in the statistical analysis of variance model, but
were included in the continuous linear regression as shown in
Fig. 4.
The relationship between CLCR and edivoxetine CL/F is
illustrated in Fig. 4. The slope of the linear regression was
statistically different from zero (p-value: 0.0457) and the
correlation coefficient was 0.3449. Based on linear regression,
the y-intercept (CLCR=0; no theoretical renal function) for
CL/F was 15.7 L/h, which is within range of CL/F of many
subjects in this study across varying renal impairment groups.
The model predicted mean CL/F (95 % predicted CI) in-
creased by a factor of approximately 1.8, from 16.6 L/h (0,
36.9) to 30.3 L/h (9.13, 51.5), when the CLCR increased by a
factor of approximately 20 indicating that a considerable
change in CLCR is needed to have an impact on CL/F.
Urine was not collected and analyzed for concentrations of
edivoxetine in the renal impairment study. Previous evalua-
tions demonstrated that unmetabolized edivoxetine was not
principally eliminated from the body via the urine (<18 % of
the dose) and that edivoxetine renal clearance contributed
about 20 % of total body clearance. The degree to which the
kidney plays a role in edivoxetine elimination is reflected by
the effect of renal impairment on edivoxetine PK in this study.
Plasma protein binding evaluations were not conducted in
the renal impairment study. It had been determined previously
that the extent of edivoxetine binding to human plasma pro-
tein was approximately 65 % and drug concentration inde-
pendent. According to the FDA guidance [7], a potential
alteration in protein binding due to impaired renal function
for drugs with an extent of binding less than 80 % would
likely lead to a relatively minor change in the unbound frac-
tion of circulating drug. As such, total edivoxetine plasma
concentrations were deemed to be adequate and were exclu-
sively used in the PK analyses in this study.
Safety and tolerability
Hepatic impairment
No deaths occurred, and no subjects discontinued because of
an AE. Of the 36 subjects who received edivoxetine, 20
(56 %) experienced a total of 44 treatment-emergent AEs
(TEAEs), with 16 (44 %) of these subjects reporting 31 AEs
that were considered by the investigator to be related to
edivoxetine. In each hepatic function group, the majority of
AEs reported were mild in severity, with no serious or severe
adverse events reported. Moderate AEs were reported by three
subjects during the study, including vomiting reported by a
subject in the normal group, somnolence reported by a subject
with mild hepatic impairment, and tinnitus, feeling abnormal,
headache, and fatigue reported by a subject with moderate
hepatic impairment. Across all groups, the most commonly
reported AEs were nervous system disorders including dizzi-
ness, headache, and somnolence, and gastrointestinal disorders
including nausea, constipation, vomiting, abdominal discomfort,
and dry mouth. No clinically significant changes in laboratory
values and vital signs were reported.
Renal impairment
No deaths occurred, and no subjects discontinued because of
an AE. There was one report of a serious AE by a subject with
ESRD receiving hemodialysis that developed a clotted fistula,
classified as a malfunctioning vascular device/graft, which
required hospitalization to replace the device with a perma-
nent catheter. This event was not judged by the investigator to
be related to edivoxetine. Of the 42 subjects who received
edivoxetine, 14 reported TEAEs. Of the 14 subjects that
reported TEAEs, eight reported TEAEs that were judged by
the investigator to be related to edivoxetine. Most TEAEs
were of mild severity, and the most common TEAEs were
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Fig. 1 Arithmetic mean edivoxetine plasma concentration-time profiles
after a single oral administration of 18 mg edivoxetine to subjects with
varying degrees of hepatic function (upper panel a : linear scale; lower
panel b : semi-logarithmic scale)
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nausea and dizziness. One subject with ESRD reported 2
TEAEs of urinary hesitation judged by the investigator to be
moderate in severity. While there were no TEAEs reported in the normal group, the number of reported AEs did not increase
with the degree of renal impairment. No clinically significant
changes in laboratory values or vital signs were reported. In
subjectswith renal impairment, predicted out-of-range laboratory
and ECG parameters were noted, but did not appear to impact
overall subject safety.
Discussion
The doses of edivoxetine evaluated as adjunctive treatment for
adults withMDD range from 6mg to 18mg [8–11]. The doses
investigated in the renal and hepatic studies were 6 mg and
18 mg, respectively. The dose in the renal study was lower
because understanding of the safety, PK, and pharmacody-
namics of edivoxetine at the time the renal study was
conducted was not as extensive relative to when the hepatic
study was conducted; as a result, a conservative renal study
design was implemented. Nevertheless, based on exposure
and safety data obtained from subsequent clinical studies up
to a top dose of 36 mg, the PK of edivoxetine appears to be
concentration independent (linear clearance) and time inde-
pendent (stationary). For these reasons, the results obtained
from the renal and hepatic studies can be reasonably applied to
a wide dose range of edivoxetine.
The heterogeneity of the demographics (Table 1) within the
studies is worth noting. In the renal study, there was large
variability in the number of subjects at each group, and the
normal group was comprised of only female subjects, whereas
the impaired groups contained mostly males that weighed
more than the females. The age across groups was mostly
similar, except for the ESRD group receiving hemodialysis,
which was considerably younger than all other groups. In the
hepatic study, the differences across groups based on age, race
Child-Pugh Total Score
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Child-Pugh C - Severe hepatic impairment
Fig. 2 Relationship between Child–Pugh total score and edivoxetine oral
clearance (CL/F)
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Fig. 3 Arithmetic mean edivoxetine plasma concentration-time profiles
after a single oral administration of 6 mg edivoxetine to subjects with
varying degrees of renal function (upper panel a : linear scale; lower panel
b : semi-logarithmic scale)
Estimated Creatinine Clearance (mL/min)

























ESRD not receiving hemodialysis
Fig. 4 Relationship between estimated creatinine clearance and
edivoxetine oral clearance (CL/F)
Eur J Clin Pharmacol (2013) 69:2011–2019 2017
or sex were less prominent than in the renal study. Results of
our analysis demonstrated that there is a slight trend for lower
CL/F when CLCR is reduced in renally impaired subjects or
when the Child–Pugh score is increased in hepatically im-
paired subjects. Furthermore, a continuous regression analysis
was used to evaluate the effect of renal or hepatic function on
CL/F due to the variability in demography across study groups
that could possibly skew categorical results. Diversity in sub-
ject demographics was not anticipated to have a significant
impact on PK based on a previous clinical investigation that
showed edivoxetine exposure was only mildly increased in
elderly subjects compared to young subjects, and within el-
derly subjects aged 65–81 years there was no difference in
exposure [unpublished data]. Similarly, preliminary evalua-
tions using a population PK analysis approach demonstrated
that sex and body weight were not covariates of edivoxetine
PK in adults [unpublished data]. For these reasons, the PK
results obtained from the renal and hepatic impairment studies
are considered to be valid.
In the hepatically impaired subjects, the increase in
AUC0-∞ was of small magnitude and was not appreciably
different in the moderate and severe groups. A delay of 1 to
2 days to reach steady state (SS) plasma concentrations is
expected in the moderate and severe groups due to the in-
crease in t1/2, but this change is not believed to have any
clinical consequence on the safety or efficacy of the drug.
An increase in bioavailability cannot be ruled out as a possible
contributing factor to the increase in AUC0-∞. A slight de-
crease was observed in Cmax and increase in tmax in hepatically
impaired subjects, which were consistent with a presumed
decrease in the rate of edivoxetine absorption. While the exact
mechanism for reduced edivoxetine CL/F is unknown, it was
previously established that edivoxetine is metabolized in the
liver primarily by cytochrome P450 (CYP) 2D6 [12] and
CYP3A enzymes and is excreted with metabolites into feces
and, to a minor extent, in urine [unpublished data]. It is
possible that the activity or the metabolic capacity of enzymes
responsible for the metabolism of edivoxetine is compromised
to some degree in hepatically impaired subjects. However, it
should be noted that while the Child–Pugh scale is the most
commonly used method for classifying subjects with hepatic
impairment in clinical trials, this scale was not developed for
the purpose of predicting drug elimination capacity. The anal-
ysis indicated that the correlation between Child-Pugh score
and edivoxetine CL/F was not statistically significant and
corroborates our categorical analysis of PK parameters across
the impairment groups.
In renally impaired subjects, a modest increase in t1/2 and
AUC0-∞ was observed but was not correlated with the
degree of renal impairment. Renal impairment can lead to
alterations in bioavailability and nonrenal clearance by affect-
ing pathways of intestinal and hepatic drug-metabolizing en-
zymes and transporters [13–16]. As CYP450 enzymes are
known to metabolize edivoxetine, an increase in bioavailabil-
ity and/or reduced elimination from the body (based on t1/2)
may account for the observed increase in AUC0-∞ in renally
impaired subjects.
Following a single dose of edivoxetine, hepatic or renal
impairment did not appear to impact overall subject tolerabil-
ity in these studies. The AEs reported were similar across the
renal and hepatic studies, mild in severity, and similar to
previously reported clinical investigations with edivoxetine
in healthy subjects that achieved similar plasma exposures.
Although the data obtained did not raise any safety and
tolerability concerns, the studies were conducted in a small
patient population, of which subjects had either renal or he-
patic impairment, but not both. Daily dosing of edivoxetine in
a larger population of impaired subjects, including those with
varying degrees of dual impairment, would aid in establishing
edivoxetine tolerability and PK in a clinical practice scenario.
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